Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Sep 13;226(5):938-940.
doi: 10.1093/infdis/jiac256.

Protection Against Severe Clinical Outcomes With Adenovirus or Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Patients Hospitalized With Coronavirus Disease 2019

Josep M Llibre  1   2 , Boris Revollo  1   2 , Sergi Aguilar  3 , Cristina Calomarde-Gomez  4 , Andreu Bruguera  5 , Raquel Martin-Iguacel  5   6
Affiliations
Editorial

Protection Against Severe Clinical Outcomes With Adenovirus or Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Patients Hospitalized With Coronavirus Disease 2019

Josep M Llibre et al. J Infect Dis. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest . All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

Figure 1.
Figure 1.
A, Kaplan-Meier curves for intensive care unit (ICU) admission by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination: no primary course vaccination, vaccination with adenovirus-vectored vaccine, or vaccination with messenger RNA (mRNA) vaccine. B, Risk for ICU admission among all patients hospitalized with coronavirus disease 2019 (COVID-19), by demographic and clinical variables and vaccination status. Abbreviations: aIRR, adjusted incidence rate ratio; CI, confidence interval; IR, incidence rate; IRR, incidence rate ratio. The aIRRs were adjusted for age, type of primary course vaccination, booster vaccination, immune suppression, and number of comorbid conditions; cormorbid conditions included diabetes mellitus type II, chronic lung disease, chronic kidney disease, arterial hypertension, obesity, and human immunodeficiency virus infection.
See this image and copyright information in PMC

Comment in

  • Reply to Llibre et al.
    Šmíd M, Berec L, Trnka J. Šmíd M, et al. J Infect Dis. 2022 Sep 13;226(5):941. doi: 10.1093/infdis/jiac258. J Infect Dis. 2022. PMID: 35763365 No abstract available.

Comment on

References

    1. Šmíd M, Berec L, Přibylová L, et al. Protection by vaccines and previous infection against the Omicron variant of SARS-CoV-2. J Infect Dis 2022:jiac161. doi:10.1093/infdis/jiac161 - DOI - PMC - PubMed
    1. Hall V, Foulkes S, Insalata F, et al. Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection. N Engl J Med 2022; 386:1207–20. doi:10.1056/NEJMoa2118691 - DOI - PMC - PubMed
    1. Rosenberg ES, Dorabawila V, Easton D, et al. Covid-19 vaccine effectiveness in New York State. N Engl J Med 2022; 386:116–27. doi:10.1056/NEJMoa2116063 - DOI - PMC - PubMed
    1. Sablerolles RSG, Rietdijk WJR, Goorhuis A, et al. Immunogenicity and reactogenicity of vaccine boosters after Ad26.COV2.S priming. N Engl J Med 2022; 386:951–63. doi:10.1056/NEJMoa2116747 - DOI - PMC - PubMed
    1. Andrews N, Tessier E, Stowe J, et al. Duration of protection against mild and severe disease by Covid-19 vaccines. N Engl J Med 2022; 386:340–50. doi:10.1056/NEJMoa2115481 - DOI - PMC - PubMed